Analysts See $-0.77 EPS for Myovant Sciences Ltd. (MYOV)

May 17, 2018 - By Tina Thibodeau

Analysts expect Myovant Sciences Ltd. (NYSE:MYOV) to report $-0.77 EPS on June, 13.After having $-0.70 EPS previously, Myovant Sciences Ltd.’s analysts see 10.00 % EPS growth. The stock decreased 1.15% or $0.25 during the last trading session, reaching $21.45. About 59,955 shares traded. Myovant Sciences Ltd. (NYSE:MYOV) has risen 79.46% since May 18, 2017 and is uptrending. It has outperformed by 67.91% the S&P500.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company has market cap of $1.33 billion. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

Myovant Sciences Ltd. (NYSE:MYOV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: